Presentation is loading. Please wait.

Presentation is loading. Please wait.

Plasma concentrations of glucose, insulin, C-peptide and glucagon observed in subjects with NFG/NGT, NFG/IGT, IFG/NGT, and IFG/IGT-D following ingestion.

Published byὈφιοῦχος Μητσοτάκης Modified over 5 years ago

Similar presentations

Presentation on theme: "Plasma concentrations of glucose, insulin, C-peptide and glucagon observed in subjects with NFG/NGT, NFG/IGT, IFG/NGT, and IFG/IGT-D following ingestion."— Presentation transcript:

1 Plasma concentrations of glucose, insulin, C-peptide and glucagon observed in subjects with NFG/NGT, NFG/IGT, IFG/NGT, and IFG/IGT-D following ingestion of a mixed meal containing 75 g glucose and after ingestion of 75 g glucose alone. Plasma concentrations of glucose, insulin, C-peptide and glucagon observed in subjects with NFG/NGT, NFG/IGT, IFG/NGT, and IFG/IGT-D following ingestion of a mixed meal containing 75 g glucose and after ingestion of 75 g glucose alone. Gerlies Bock et al. Diabetes 2007;56: ©2007 by American Diabetes Association

Download ppt "Plasma concentrations of glucose, insulin, C-peptide and glucagon observed in subjects with NFG/NGT, NFG/IGT, IFG/NGT, and IFG/IGT-D following ingestion."

Similar presentations

Mechanisms of Glucose Lowering of Dipeptidyl Peptidase-4 Inhibitor Sitagliptin When Used Alone or With Metformin in Type 2 Diabetes A double-tracer study.

Mechanisms of Glucose Lowering of Dipeptidyl Peptidase-4 Inhibitor Sitagliptin When Used Alone or With Metformin in Type 2 Diabetes A double-tracer study.
Philip J. Barter, et al. Circulation 2011;124:555-562.

Philip J. Barter, et al. Circulation 2011;124:
Some diabetics inject insulin after a meal. Diabetics may carry a blood monitor to test the amount of glucose in the blood. Diabetics are recommended to.

Some diabetics inject insulin after a meal. Diabetics may carry a blood monitor to test the amount of glucose in the blood. Diabetics are recommended to.
Contributions to Type 2 Diabetes. Glucose in balance meal Time in minutes Blood glucose levels, mg/dL -60 0 60 120 180 240 80 Insulin levels, uU/mL Glucagon.

Contributions to Type 2 Diabetes. Glucose in balance meal Time in minutes Blood glucose levels, mg/dL Insulin levels, uU/mL Glucagon.
Plasma insulin concentrations (A) and insulin secretion rates (B) in response to molar increments of plasma glucose concentration during the graded glucose.

Plasma insulin concentrations (A) and insulin secretion rates (B) in response to molar increments of plasma glucose concentration during the graded glucose.
Mean rates of insulin and glucagon delivery from an artificial pancreas at various blood glucose levels. The device was programmed to establish and maintain.

Mean rates of insulin and glucagon delivery from an artificial pancreas at various blood glucose levels. The device was programmed to establish and maintain.
(Copyright © 1977 American Diabetes Association. Marliss EB et al

(Copyright © 1977 American Diabetes Association. Marliss EB et al
Choosing glucose-lowering medication in those with established ASCVD, HF, and CKD. CV, cardiovascular; DPP-4i, dipeptidyl peptidase 4 inhibitor; GLP-1.

Choosing glucose-lowering medication in those with established ASCVD, HF, and CKD. CV, cardiovascular; DPP-4i, dipeptidyl peptidase 4 inhibitor; GLP-1.
Glucose homeostasis: roles of insulin and glucagon. 1A.

Glucose homeostasis: roles of insulin and glucagon. 1A.
Plasma active glucagon-like peptide-1 (GLP-1) response in patients with type  2 diabetes during the liquid high-fat meal test at baseline, 12 weeks and.

Plasma active glucagon-like peptide-1 (GLP-1) response in patients with type  2 diabetes during the liquid high-fat meal test at baseline, 12 weeks and.
Insulin and glucagon secretion: nondiabetic and diabetic subjects.

Insulin and glucagon secretion: nondiabetic and diabetic subjects.
Postprandial glucose flux in nondiabetic controls.

Postprandial glucose flux in nondiabetic controls.
Relationship between plasma glucose, insulin and glucagon levels

Relationship between plasma glucose, insulin and glucagon levels
Update on cystic fibrosis-related diabetes

Update on cystic fibrosis-related diabetes
Dandan Wang et al. BTS 2018;3:350-362 Down-Regulation of miR-24 in Response to Insulin Infusion in Human Plasma Human plasma insulin (A), glucose (B),

Dandan Wang et al. BTS 2018;3: Down-Regulation of miR-24 in Response to Insulin Infusion in Human Plasma Human plasma insulin (A), glucose (B),
Fasting plasma adiponectin concentration in relation to body mass index (BMI) (A), waist circumference (B), acute insulin response (AIR) (C) and insulin.

Fasting plasma adiponectin concentration in relation to body mass index (BMI) (A), waist circumference (B), acute insulin response (AIR) (C) and insulin.
Mean daily glucose concentration and frequency of hypoglycemia in long-term care residents with type 2 diabetes. Mean daily glucose concentration and frequency.

Mean daily glucose concentration and frequency of hypoglycemia in long-term care residents with type 2 diabetes. Mean daily glucose concentration and frequency.
Blood glucose, insulin and C-peptide concentrations (A), insulin dose received and BGC (B) for one neonate treated with insulin over 24 hours. Blood glucose,

Blood glucose, insulin and C-peptide concentrations (A), insulin dose received and BGC (B) for one neonate treated with insulin over 24 hours. Blood glucose,
What is type 2 diabetes? Medicine

What is type 2 diabetes? Medicine
One- to two-hour plasma glucose concentrations over a 24-hour period in patients taking maximal doses of either glyburide (20 mg/day) or glipizide (40.

One- to two-hour plasma glucose concentrations over a 24-hour period in patients taking maximal doses of either glyburide (20 mg/day) or glipizide (40.

Similar presentations

Ads by Google